Dose dense chemotherapy in the postoperative adjuvant treatment for breast cancer.
- Author:
Yi-dong ZHOU
1
;
Qiang SUN
;
Han-yuan HUAN
;
Feng MAO
;
Jing-hong GUAN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; adverse effects; therapeutic use; Breast Neoplasms; drug therapy; pathology; surgery; Chemotherapy, Adjuvant; Cyclophosphamide; administration & dosage; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; administration & dosage; Female; Fluorouracil; administration & dosage; Follow-Up Studies; Humans; Liver Neoplasms; secondary; Lymphatic Metastasis; Mastectomy; methods; Middle Aged; Nausea; chemically induced; Neutropenia; chemically induced; Paclitaxel; administration & dosage; Postoperative Period; Retrospective Studies; Taxoids; administration & dosage
- From: Chinese Journal of Oncology 2007;29(4):316-318
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the safety and feasibility of dose dense chemotherapy in the postoperative adjuvant treatment for breast cancer.
METHODSThe data of 114 breast cancer patients treated with adjuvant dose dense chemotherapy was retrospectively analyzed.
RESULTS114 breast cancer patients received postoperative adjuvant dose dense chemotherapy from Jan. 2004 to March 2005. The patients were treated with different regimens according to their recurrence risk: 43 with paclitaxel + epirubicin (PE), 8 with taxotere + epirubicin (TE), 36 with cyclophosphamide + epirubicin + 5-Fu ( CEF) and 27 with epirubicin +5-Fu (EC). Totally, 111 patients except 3 completed the dose dense chemotherapy smoothly. Major toxicities severer than grade III included: neutropenia in 6.3% of the patients, nausea and vomit in 11.7%, peripheral neuropathy in 3.6%.
CONCLUSIONPostoperative adjuvant dose dense chemotherapy for breast cancer patient is feasible and safe, but the long-term outcome still needs further observation.
